CTI Ends Key Lung Cancer Trial
Posted on: Friday, 8 December 2006, 14:51 CST
Cell Therapeutics has decided to close its Xyotax lung cancer trial because patients taking the drug were dying more rapidly than those on chemotherapy alone.
CTI still plans to continue development of Xyotax despite the setback. The drug has already failed three major lung cancer trials.
The company said it would submit a new protocol for the drug by the end of the year to the FDA. The trial will focus exclusively on women with normal estrogen levels, the subset where Xyotax has previously demonstrated the greatest survival advantage. Preclinical and clinical studies showed that Xyotax metabolism by lung cancer cells may be influenced by estrogen, which could lead to enhanced release of paclitaxel and efficacy in women with lung cancer compared to standard therapies.
The company commented that the high number of deaths were not due to contamination or toxicity and could not explain why there was a difference between the two groups. The termination of the trial could delay the company's plans by six months.
Source: Datamonitor
Related Articles
- GTx Announces Investigational Ostarine(TM) (MK-2866) Met the Primary Endpoint in the Phase II Cancer Cachexia Clinical Trial
- Generex Initiates Enrollment for Phase I Cancer Combination Therapy Trial
- Progress Analysis of Top 7 Cancer Indications, Including Players, Drugs, Clinical Progress and Pitfalls
- Cell Therapeutics, Inc. (CTI) Files for Special Protocol Assessment (SPA) With FDA for XYOTAX Lung Cancer Trial in Women
- Editorial: Cancer's Sticker Shock: New Drug May Cost $100,000 a Year
- Chiron Foundation Awards Grants to National Organizations Promoting Improved Quality of Life for Cancer and Lung Transplant Patients
- Phase I Study of High Dose Weekly ABRAXANE(TM) Published in Journal of Clinical Oncology: Responses Achieved in Patients With Taxol(R) Refractory Ovarian Cancer and Lung Cancer
- Research and Markets: Molecular Cancer Therapeutics: Strategies for Drug Discovery and Development
- Peregrine Pharmaceuticals Opens Patient Enrollment for Its Tarvacin(TM) Phase I Solid Cancer Therapy Clinical Trial
- Trial Drugs Offer Hope for Brain Cancer
 |
 |
User Comments (0)
RSS Feeds